Related Experiment Video
Updated: Nov 30, 2025
08:40
An Optimized Protocol to Analyze Glycolysis and Mitochondrial Respiration in Lymphocytes
Published on: November 21, 2016
30.5K
Glycolytic inhibition: an effective strategy for developing calorie restriction mimetics
Donald K Ingram1, George S Roth2
1Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins Road, Baton Rouge, LA, 70809, USA. donald.ingram@pbrc.edu.
Geroscience
|November 13, 2020
Summary
Calorie restriction mimetics aim to replicate anti-aging benefits without dietary changes. This review focuses on glycolytic inhibition strategies, exploring compounds like 2-deoxyglucose for potential anti-aging, anti-cancer, and anti-obesity effects.
Area of Science:
- Biochemistry
- Gerontology
- Pharmacology
Background:
- Calorie restriction (CR) extends lifespan and healthspan by activating conserved cellular pathways.
- Developing CR mimetics offers a non-dietary approach to harness CR's benefits.
- Glycolytic inhibition is a key upstream strategy to mimic CR's effects.
Purpose of the Study:
- To review approaches targeting glycolytic inhibition as a CR mimetic strategy.
- To highlight compounds investigated for their potential to induce CR-like effects.
- To discuss anti-cancer and anti-obesity applications of these inhibitors.
Main Methods:
- Literature review of scientific publications on CR mimetics.
- Focus on compounds inhibiting intracellular glycolysis.
- Analysis of selected compounds including 2-deoxyglucose, 3-bromopyruvate, and resveratrol.
Main Results:
- Glycolytic inhibition is a promising strategy to activate CR-induced anti-aging mechanisms.
- Several compounds show potential, but results vary, with some extensively studied and others emerging.
- Anti-cancer and anti-obesity effects are key considerations in evaluating these candidates.
Conclusions:
- Glycolytic inhibitors represent a significant area of research for developing CR mimetics.
- Further investigation is needed to optimize efficacy and safety of these compounds.
- Targeting glycolysis offers a potential route to anti-aging, anti-cancer, and anti-obesity therapeutics.
Related Concept Videos
01:19Regulation of Metabolism
10.9K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
10.9K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
422
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
422
02:34Inhibition of Cdk Activity
5.4K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
01:30Enzyme Inhibition
89.2K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
89.2K
01:24Glucagon-like Receptor Agonists
642
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
642